Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis
How thrombophilia may contribute to the development of chronic thromboembolic pulmonary hypertension (CTEPH) is unknown. We searched on PubMed and EMBASE (until 15 April 2018), studies on CTEPH reporting data on inherited or acquired thrombophilia. Starting from 367 articles mentioning the search terms, 347 were excluded mainly as duplicate articles or articles not in English. After reading the full text of remaining articles, ten were excluded for being reviews, editorials, letters or case reports, and two were further removed from the analysis because of the potential selection bias. All the eight considered studies provided the proportion of patients positive for antiphospholipid (aPL) antibodies. The crude rate of aPL in CTPEH patients is 11.8% (95% CI 10.09–13.8%). The meta-analysis considering the weighted mean proportion and 95% confidence intervals (CIs) yields a rate of aPL antibody-positive profile of 12.06% (95% CI 8.12–16.65%) among the patients with CTEPH in the random effects model (I2 76.33%; 95% CI 52.75–88.14%, p = 0.0001). The sensibility analysis confirms the result. No predictors of heterogeneity are found in a meta-regression analysis. Our results suggest that aPL antibodies are frequently associated with CTEPH underlining the need to test for aPL antibodies in young patients with “idiopathic” and “provoked” PE caused by mild provoking risk factors.
KeywordsInherited thrombophilia Antiphospholipid antibodies Chronic thromboembolic pulmonary hypertension
Supported by CAMS Innovation Fund for Medical Sciences (2017-I2M-B&R-02). Capital Characteristic Clinic Project of Beijing Municipal (Z181100001718203). National Science Fund for Distinguished Young Scholars (81425002). The funding sources had no role in the study design, data selection and analysis, quality assessment, data synthesis and interpretation, or the decision to prepare and submit the manuscript for publication.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statements on human and animal rights
The procedures followed in this study are in accordance with the ethical standards and to our knowledge, no unethical study was included in the meta-analysis. Aggregate data (meta-analyses) are likely to have the same objectives as the original studies.
There is no particular ethical problem regarding the original informed consent of patients.
- 4.Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P, Thromboembolic Pulmonary Hypertension Study G (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350(22):2257–2264. https://doi.org/10.1056/nejmoa032274 CrossRefGoogle Scholar
- 7.Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D’Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barbera JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jais X, Simonneau G (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124(18):1973–1981. https://doi.org/10.1161/CIRCULATIONAHA.110.015008 CrossRefGoogle Scholar
- 8.Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schonauer V, Exner M, Klepetko W, Kneussl MP, Maurer G, Lang I (2005) Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93(3):512–516. https://doi.org/10.1160/TH04-10-0657 CrossRefGoogle Scholar
- 13.Feinbloom D, Bauer KA (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 25(10):2043–2053. https://doi.org/10.1161/01.ATV.0000181762.31694.da CrossRefGoogle Scholar
- 17.D’Armini AM, Totaro P, Nicolardi S, Morsolini M, Silvaggio G, Toscano F, Toscano M, Vigano M (2010) Impact of high titre of antiphospholipid antibodies on postoperative outcome following pulmonary endarterectomy. Interact Cardiovasc Thorac Surg 10(3):418–422. https://doi.org/10.1510/icvts.2009.221630 CrossRefGoogle Scholar
- 19.Sompradeekul S, Minipan M (2010) Clinical features and management of chronic thromboembolic pulmonary hypertension in Thai. J Med Assoc Thai 93(Suppl 1):S79–S85Google Scholar
- 28.Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x CrossRefGoogle Scholar
- 29.Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237–242. https://doi.org/10.1111/j.1538-7836.2009.03674.x CrossRefGoogle Scholar
- 30.Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907. https://doi.org/10.1056/NEJM199903253401201 CrossRefGoogle Scholar
- 34.Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM (2009) Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 33(2):325–331. https://doi.org/10.1183/09031936.00087608 CrossRefGoogle Scholar
- 37.Yang S, Yang Y, Zhai Z, Kuang T, Gong J, Zhang S, Zhu J, Liang L, Shen YH, Wang C (2015) Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. J Thorac Dis 7(11):1927–1938. https://doi.org/10.3978/j.issn.2072-1439.2015.11.43 Google Scholar
- 39.Cosmi B, Legnani C, Pengo V, Ghirarduzzi A, Testa S, Poli D, Prisco D, Tripodi A, Palareti G, Investigators P (2013) The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. Thromb Haemost 109(3):510–516. https://doi.org/10.1160/TH12-01-0041 CrossRefGoogle Scholar
- 40.Lang IM, Klepetko W, Pabinger I (1996) No increased prevalence of the factor V Leiden mutation in chronic major vessel thromboembolic pulmonary hypertension (CTEPH). Thromb Haemost 76(3):476–477Google Scholar
- 41.Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the S, Standardisation Committee of the International Society on T, Haemostasis (2009) Update of the guidelines for lupus anticoagulant detection Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7(10):1737–1740. https://doi.org/10.1111/j.1538-7836.2009.03555.x CrossRefGoogle Scholar